Opioid Antagonists

Journal of Pain and Symptom Management

Volumn 47, Issue 2, 2014, Pages 341-352

  Barnett, Victoria ^a   Twycross, Robert ^a   Mihalyo, Mary ^a   Wilcock, Andrew ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONIST; QUATERNARY AMMONIUM DERIVATIVE;

ANALOGS AND DERIVATIVES; HOSPICE CARE; HUMAN; INTERNET; PALLIATIVE THERAPY;

HOSPICE CARE; HUMANS; INTERNET; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PALLIATIVE CARE; QUATERNARY AMMONIUM COMPOUNDS;

EID: 84905493907     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2013.12.223     Document Type: Short Survey

References (108)

1. Wolfhagen, F.H., Sternieri, E., Hop, W.C., et al. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 113 (1997), 1264–1269.
2. Peer, G., Kivity, S., Agami, O., et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348 (1996), 1552–1554.
3. Pauli-Magnus, C., Mikus, G., Alscher, D.M., et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11 (2000), 514–519.
4. Choi, Y.S., Billings, J.A., Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 24 (2002), 71–90.
5. Gan, T.J., Ginsberg, B., Glass, P.S., et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87 (1997), 1075–1081.
6. Joshi, G.P., Duffy, L., Chehade, J., et al. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 90 (1999), 1007–1011.
7. Cepeda, M.S., Alvarez, H., Morales, O., Carr, D.B., Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 107 (2004), 41–46.
8. Maxwell, L.G., Kaufmann, S.C., Bitzer, S., et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 100 (2005), 953–958.
9. Murphy, J.D., Gelfand, H.J., Bicket, M.C., et al. Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis. J Opioid Manag 7 (2011), 321–327.
10. Levine, J.D., Gordon, N.C., Fields, H.L., Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 278 (1979), 740–741.
11. Levine, J., Gordon, N., Synergism between the analgesic actions of morphine and pentazocine. Pain 33 (1988), 369–372.
12. Hill, R.G., Multiple opioid receptors and their ligands. Frontiers of Pain 4 (1992), 1–4.
13. Chindalore, V.L., Craven, R.A., Yu, K.P., et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 6 (2005), 392–399.
14. Largent-Milnes, T.M., Guo, W., Wang, H.Y., Burns, L.H., Vanderah, T.W., Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling. J Pain 9 (2008), 700–713.
15. Hay, J.L., La Vincente, S.F., Somogyi, A.A., Chapleo, C.B., White, J.M., Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. Eur J Pain 15 (2011), 293–298.
16. Cruciani, R.A., Lussier, D., Miller-Saultz, D., Arbuck, D.M., Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage 25 (2003), 491–494.
17. Hamann, S., Sloan, P., Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study. J Opioid Manag 3 (2007), 137–144.
18. Crain, S., Shen, K., Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84 (2000), 121–131.
19. Sjøgren, P., Jensen, N.H., Jensen, T.S., Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid antagonists. Pain 59 (1994), 313–316.
20. Wang, H.Y., Burns, L.H., Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One, 4, 2009, e4282.
21. Milligan, E.D., Watkins, L.R., Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10 (2009), 23–36.
22. Ren, K., Dubner, R., Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol 21 (2008), 570–579.
23. Yang, C.P., Cherng, C.H., Wu, C.T., et al. Intrathecal ultra-low dose naloxone enhances the antinociceptive effect of morphine by enhancing the reuptake of excitatory amino acids from the synaptic cleft in the spinal cord of partial sciatic nerve-transected rats. Anesth Analg 113 (2011), 1490–1500.
24. Twycross, R., Wilcock, A., Toller, C.S., Symptom management in advanced cancer. 4th ed., 2009, palliativedrugs.com Ltd., Nottingham, 43–45.
25. Foster, B., Twycross, R., Mihalyo, M., Wilcock, A., Buprenorphine. J Pain Symptom Manage 45 (2013), 939–949.
26. Raffa, R.B., Friderichs, E., Reimann, W., et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 260 (1992), 275–285.
27. Shipton, E.A., Tramadol - present and future. Anaesth Intensive Care 28 (2000), 363–374.
28. Marquardt, K.A., Alsop, J.A., Albertson, T.E., Tramadol exposures reported to statewide poison control system. Ann Pharmacother 39 (2005), 1039–1044.
29. Horng, H.C., Ho, M.T., Huang, C.H., Yeh, C.C., Cherng, C.H., Negative pressure pulmonary edema following naloxone administration in a patient with fentanyl-induced respiratory depression. Acta Anaesthesiol Taiwan 48 (2010), 155–157.
30. Ridgway, Z.A., Pountney, A.J., Acute respiratory distress syndrome induced by oral methadone managed with non-invasive ventilation. Emerg Med J, 24, 2007, 681.
31. Feeney, C., Ani, C., Sharma, N., Frohlich, T., Morphine-induced cardiogenic shock. Ann Pharmacother, 45, 2011, e30.
32. Clarke, S.F., Dargan, P.I., Jones, A.L., Naloxone in opioid poisoning: walking the tightrope. Emerg Med J 22 (2005), 612–616.
33. Paranthaman, S.K., Khan, F., Acute cardiomyopathy with recurrent pulmonary edema and hypotension following heroin overdosage. Chest 69 (1976), 117–119.
34. Verebey, K., The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr 28 (1981), 147–158.
35. Volpicelli, J.R., Alterman, A.I., Hayashida, M., O'Brien, C.P., Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 (1992), 876–880.
36. Swift, R.M., Whelihan, W., Kuznetsov, O., Buongiorno, G., Hsuing, H., Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151 (1994), 1463–1467.
37. Krupitsky, E., Nunes, E.V., Ling, W., et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377 (2011), 1506–1513.
38. Webster, L.R., Brewer, R., Wang, C., et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 40 (2010), 734–746.
39. Oxycodone. Twycross, R., Wilcock, A., (eds.) Palliative care formulary, 4th ed., 2011, Palliativedrugs.com Ltd., Nottingham, 424–429.
40. Johnson, F., Setnik, B., Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician 14 (2011), 391–406.
41. Webster, L., Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 10:Suppl 2 (2009), S124–S133.
42. McNicol, E.D., Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev, 2008, CD006332.
43. Becker, G., Blum, H.E., Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 373 (2009), 1198–1206.
44. Ford, A.C., Brenner, D.M., Schoenfeld, P.S., Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 108 (2013), 1566–1574.
45. Larkin, P.J., Sykes, N.P., Centeno, C., et al. European Consensus Group on Constipation in Palliative Care. The management of constipation in palliative care: clinical practice recommendations. Palliat Med 22 (2008), 796–807.
46. Deibert, P., Xander, C., Blum, H.E., Becker, G., Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid 4 (2010), 247–258.
47. Anissian, L., Schwartz, H.W., Vincent, K., et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med 7 (2012), 67–72.
48. Sawh, S.B., Selvaraj, I.P., Danga, A., et al. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc 87 (2012), 255–259.
49. Weinstock, L.B., Chang, A.C., Methylnaltrexone for treatment of acute colonic pseudo-obstruction. J Clin Gastroenterol 45 (2011), 883–884.
50. Davis, M., Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics. Clin Pharmacokinet 46 (2007), 825–850.
51. Metze, D., Reimann, S., Beissert, S., Luger, T., Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 41 (1999), 533–539.
52. Jones, E.A., Neuberger, J., Bergasa, N.V., Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 95 (2002), 547–552.
53. Tandon, P., Rowe, B.H., Vandermeer, B., Bain, V.G., The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 102 (2007), 1528–1536.
54. Bergasa, N.V., Talbot, T.L., Alling, D.W., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102 (1992), 544–549.
55. Bergasa, N.V., Alling, D.W., Talbot, T.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med 123 (1995), 161–167.
56. Kumar, N., Garg, N., Bailey, A., Opiate receptor antagonists for treatment of severe pruritus associated with advanced cholestatic liver disease. J Palliat Med 16 (2013), 122–123.
57. Terg, R., Coronel, E., Sordá, J., Muñoz, A.E., Findor, J., Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 37 (2002), 717–722.
58. Bergasa, N.V., Alling, D.W., Talbot, T.L., Wells, M.C., Jones, E.A., Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 41 (1999), 431–434.
59. Jones, E., Dekker, L., Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 118 (2000), 431–432.
60. McRae, C.A., Prince, M.I., Hudson, M., et al. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 125 (2003), 591–596.
61. Lonsdale-Eccles, A.A., Carmichael, A.J., Opioid antagonist for pruritus of cholestasis unmasking bony metastases. Acta Derm Venereol, 89, 2009, 90.
62. Chan, K.Y., Li, C.W., Wong, H., et al. Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. J Palliat Med 6 (2013), 966–970.
63. Juby, L.D., Wong, V.S., Losowsky, M.S., Buprenorphine and hepatic pruritus. Br J Clin Pract, 48, 1994, 331.
64. Reddy, L., Krajnik, M., Zylicz, Z., Transdermal buprenorphine may be effective in the treatment of pruritus in primary biliary cirrhosis. J Pain Symptom Manage 34 (2007), 455–456.
65. Marinangeli, F., Guetti, C., Angeletti, C., et al. Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus. J Pain Symptom Manage 38 (2009), e5–e8.
66. Zylicz, Z., Stork, N., Krajnik, M., Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report. J Pain Symptom Manage 29 (2005), 100–103.
67. Jones, E.A., Zylicz, Z., Treatment of pruritus caused by cholestasis with opioid antagonists. J Palliat Med 8 (2005), 1290–1294.
68. Manenti, L., Tansinda, P., Vaglio, A., Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs 69 (2009), 251–263.
69. Kumagai, H., et al. Endogenous opioid system in uraemic patients. Abstracts from the Joint Meeting of the Seventh World Conference on Clinical Pharmacology and IUPHAR - Division of Clinical Pharmacology and the Fourth Congress of the European Association for Clinical Pharmacology and Therapeutics Br J Pharmacol, 282, 2000.
70. Odou, P., Azar, R., Luyckx, M., Brunet, C., Dine, T., A hypothesis for endogenous opioid peptides in uraemic pruritus: role of enkephalin. Nephrol Dial Transplant 16 (2001), 1953–1954.
71. Wikström, B., Gellert, R., Ladefoged, S.D., et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16 (2005), 3742–3747.
72. Phan, N.Q., Bernhard, J.D., Luger, T.A., Ständer, S., Antipruritic treatment with systemic u-opioid receptor antagonists; a review. J Am Acad Dermatol 63 (2010), 680–688.
73. Opioid antagonists. Twycross, R., Wilcock, A., (eds.) Palliative care formulary, 4th ed., 2011, Palliativedrugs.com Ltd., Nottingham, 328–336.
74. Spinal analgesia. Twycross, R., Wilcock, A., (eds.) Palliative care formulary, 4th ed., 2011, Palliativedrugs.com Ltd., Nottingham, 509–517.
75. Peters, W.P., Johnson, M.W., Friedman, P.A., Mitch, W.E., Pressor effect of naloxone in septic shock. Lancet 1 (1981), 529–532.
76. Cohen, R.A., Coffman, J.D., Naloxone reversal of morphine-induced peripheral vasodilatation. Clin Pharmacol Ther 28 (1980), 541–544.
77. Baskin, D.S., Hosobuchi, Y., Naloxone reversal of ischaemic neurological deficits in man. Lancet 2 (1981), 272–275.
78. Bousigue, J.Y., Giraud, L., Fournié, D., Trémoulet, M., Naloxone reversal of neurological deficit. Lancet 2 (1982), 618–619.
79. Ray, D., Tai, Y., Infusions of naloxone in thalamic pain. BMJ 296 (1988), 969–970.
80. Smith, J.P., Bingaman, S.I., Mauger, D.T., et al. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials 2010 (2010), 37–48.
81. Donahue, R.N., McLaughlin, P.J., Zagon, I.S., Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med 236 (2011), 1036–1050.
82. McLaughlin, P.J., Zagon, I.S., The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease. Biochem Pharmacol 84 (2012), 746–755.
83. Gonzalez, J., Brogden, R., Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35 (1988), 192–213.
84. Crabtree, B., Review of naltrexone: a long-acting opiate antagonist. Clin Pharm 3 (1984), 273–280.
85. Yancey-Wrona, J., Dallaire, B., Bilsky, E., et al. 6beta-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med 12 (2011), 1727–1737.
86. Gutstein, H.B., Akil, H., Opioid analgesics. Hardman, J.G., Limbird, L.E., Gilman, A.G., (eds.) Goodman & Gilman's The pharmacological basis of therapeutics, 10th ed., 2001, McGraw-Hill, New York, 569–620.
87. Vickers, A.P., Jolly, A., Naltrexone and problems in pain management. BMJ 332 (2006), 132–133.
88. Mitchell, J., Naltrexone and hepatotoxicity. Lancet, 1, 1986, 1215.
89. Partridge, B.L., Ward, C.F., Pulmonary oedema following low-dose naloxone administration. Anesthesiology 65 (1986), 709–710.
90. Yoburn, B.C., Luke, M.C., Pasternak, G.W., Inturrisi, C.E., Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE. Life Sci 43 (1988), 1319–1324.
91. Slatkin, N.E., Lynn, R., Su, C., Wang, W., Israel, R.J., Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage 42 (2011), 754–760.
92. Mackey, A.C., Green, L., Greene, P., Avigan, M., Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 40 (2010), e1–e3.
93. Sweetman, S.C., (eds.) Martindale: the complete drug reference (online edition), 2012, Pharmaceutical Press, London Available from www.medicinescomplete.com Accessed October 15, 2013.
94. Kintz, P., Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 121 (2001), 65–69.
95. Häkkinen, M., Launiainen, T., Vuori, E., Ojanperä, I., Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning. Eur J Clin Pharmacol 68 (2012), 301–309.
96. Budd, K., Raffa, R., (eds.) Buprenorphine - the unique opioid analgesic, 2005, Georg Thieme Verlag, Stuttgart, 134.
97. Dahan, A., Aarts, L., Smith, T.W., Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 112 (2010), 226–238.
98. Orwin, J.M., The effect of doxapram on buprenorphine induced respiratory depression. Acta Anaesthesiol Belg 28 (1977), 93–106.
99. Cleary, J., Incidence and characteristics of naloxone administration in medical oncology patients with cancer pain. J Pharm Care Pain Symptom Control 8 (2000), 65–73.
100. Miaskowski, C., Bair, M., Chou, R., et al. Principles of analgesic use in the treatment of acute pain and cancer pain. 6th ed., 2008, American Pain Society, Skokie, IL, 31.
101. Twycross, R., Sykes, N., Mihalyo, M., Wilcock, A., Stimulant laxatives and opioid-induced constipation. J Pain Symptom Manage 43 (2012), 306–313.
102. Watkins, J.L., Eckmann, K.R., Mace, M.L., et al. Utilization of methylnaltrexone (Relistor) for opioid-induced constipation in an oncology hospital. P T 36 (2011), 33–36.
103. Portenoy, R.K., Thomas, J., Moehl Boatwright, M.L., et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35 (2008), 458–468.
104. Thomas, J., Karver, S., Cooney, G.A., et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358 (2008), 2332–2343.
105. Slatkin, N., Thomas, J., Lipman, A.G., et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 7 (2009), 39–46.
106. Michna, E., Blonsky, E.R., Schulman, S., et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 12 (2011), 554–562.
107. Candy, B., Jones, L., Goodman, M.L., Drake, R., Tookman, A., Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev, 2011, CD003448.
108. Bergasa, N.V., Schmitt, J.M., Talbot, T.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27 (1998), 679–684.